Fig. 1From: Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)Patient disposition in periods 1 (12-week, placebo-controlled) and 2 (blinded extension; cut-off December 26, 2018). AE, adverse eventBack to article page